



Title	Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation
Author(s)	Hamada, Ryota; Kondo, Tadakazu; Murao, Masanobu; Miyasaka, Jyunsuke; Yoshida, Michiko; Nankaku, Manabu; Kanda, Junya; Takaori-Kondo, Akifumi; Ikeguchi, Ryosuke; Matsuda, Shuichi
Citation	Supportive Care in Cancer (2020), 28: 3189-3196
Issue Date	2020-07
URL	http://hdl.handle.net/2433/254177
Right	This is a post-peer-review, pre-copyedit version of an article published in Supportive Care in Cancer. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00520-019-05124-1.; The full-text file will be made open to the public on 12 November 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.
Туре	Journal Article
Textversion	author

1	Effect	of	the	severity	of	acute	graft-versus-host	disease	on	physical	function	after	allogeneic
2	hemato	opoi	ietic	stem cell	tra	nsplan	tation						

- 4 Running title: effect of acute GVHD on physical function
- 5 Ryota Hamada(P. T.)<sup>1</sup>, Tadakazu Kondo(MD, Ph.D.)<sup>2</sup>, Masanobu Murao(P. T.)<sup>1</sup>, Jyunsuke
- 6 Miyasaka(P. T.)<sup>1</sup>, Michiko Yoshida(P. T.)<sup>1</sup>, Manabu Nankaku(P. T, Ph.D.)<sup>1</sup>, Junya Kanda(MD,
- 7 Ph.D.)<sup>2</sup>, Akifumi Takaori-Kondo (MD, Ph.D.)<sup>2</sup>, Ryosuke Ikeguchi (MD, Ph.D.)<sup>1</sup>, Shuichi
- 8 Matsuda(MD, Ph.D.) $^{1}$
- <sup>1</sup> Rehabilitation Unit, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto
  606-8507, Japan
- 10 000-0507, **J**apan
- <sup>11</sup> <sup>2</sup> Department of Hematology and Oncology, Graduate of School of Medicine, Kyoto University,
- 12 Shogoin, 54 Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- 13
- 14 Corresponding author: Tadakazu Kondo
- 15 Department of Hematology and Oncology, Graduate of School of Medicine, Kyoto University
- 16 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto city, Kyoto 606-8507, Japan
- 17 TEL: +81-75-751-3111 FAX: +81-75-751-3201
- 18 Email: tadakazu@kuhp.kyoto-u.ac.jp
- 19
- 20 Abstract

21	Purpose
----	---------

The purpose of this study was to retrospectively investigate the effect of the severity of acute graft-versus-host disease (acute GVHD) on physical function after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

25 Methods

76 patients were included as subjects of this study. Severity of acute GVHD was classified
according to the method defined by Grucksberg. To evaluate physical function, the knee extensor
strength and six-minute walk distance (6MWD) were performed.

29 Results

Among these patients, 54% developed acute GVHD; of these 32%, 54%, and 15% of patients had Grade I, Grade II, and Grade III-IV GVHD, respectively. In the Grade I- II groups, mild acute GVHD following allo-HSCT, resulted in a gradual decline in physical function, which improved at discharge. However, in cases of severe acute GVHD, physical function deteriorated, implementation of rehabilitation became difficult, and the decline in physical function persisted even at discharge.

## 36 Conclusion

These results indicate that severe acute GVHD negatively affects physical function leading to
 longer hospital days because of inadequate rehabilitation interventions.

39 Keywords

40 allogeneic hematopoietic stem cell transplantation (allo-HSCT) · acute graft-versus-host disease

41	(acute GVHD) $\cdot$ six-minute walk distance (6MWD) $\cdot$ knee extensor strength
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	Introduction
59	Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapeutic measure
60	for hematopoietic neoplastic diseases such as leukemia and malignant lymphoma, and

61	non-neoplastic diseases such as aplastic anemia. Advancement in supportive care including
62	conditioning regimens, antibiotics, and immunosuppressant agents have significantly reduced
63	transplantation-related mortality and improved survival rate after transplantation [1]. On the other
64	hand, a decline in physical function after allo-HSCT has been recently recognized as a new concern,
65	and complications after allo-HSCT are considered as one of the factors responsible [2]. The major
66	complication after allo-HSCT is acute graft-versus-host disease (GVHD). Acute GVHD is caused
67	by lymphocytes derived from donors recognizing the normal organ of the recipient as foreign.
68	Acute GVHD is characterized by selective damage to the skin, liver, and the gastrointestinal tract.
69	Currently, it has been reported that moderate to severe acute GVHD develops in about 20% of
70	patients after allo-HSCT, regardless of the Human leukocyte Antigen (HLA) disparity, conditioning
71	regimen, or the use of immunosuppressive agents [3-4]. High-dose corticosteroid is the standard
72	first-line therapeutic drug in acute GVHD. The use of corticosteroid is designed to suppress the
73	donor lymphocyte-mediated immune insult on the recipient tissues. However, high doses of
74	corticosteroids are associated with the occurrence of various serious side effects, one of which is
75	skeletal muscle atrophy [5-9]. In previous reports, it has been shown that corticosteroid-induced
76	muscle atrophy develops in 40% of patients who receive high doses of corticosteroids [2].
77	Severity of acute GVHD has been classified according to the method defined by Grucksberg [10].
78	Clinical situations in which implementation of rehabilitation becomes difficult due to severe acute
79	GVHD is common. However, the effect of the severity of acute GVHD on the physical function
80	after allo-HSCT remains to be elucidated. The purpose of this study was to investigate the effect of

81 the severity of acute GVHD on physical function after allo-HSCT retrospectively.

82

## 83 Patients and Methods

A total of 147 patients who received allo-HSCT at the Kyoto University Hospital between 2010 and 84 2017 were included in this study.  $\frac{16}{16}$  patients who died during the hospitalization period and  $\frac{55}{55}$ 85 patients whose physical functions could not be evaluated were excluded, and eventually  $\frac{76}{76}$  patients 86 were included in this study. There was no significant difference in the patient characteristics and 87 physical function before transplantation between enrolled and excluded patients (data not shown). 88 Severity of acute GVHD was classified according to the method defined by Grucksberg [10]. 89 There were  $\frac{35}{35}$  patients who did not have acute GVHD during the hospital stay and  $\frac{41}{41}$  patients who 90 developed acute GVHD (Grade I: 13, Grade II: 22, Grade III-IV: 6) (Figure I). This study was 91approved by the Institutional Review Board of Kyoto University Hospital (Approval number: 92R0715). All patients were informed about the study procedures before the tests and written 93 informed consent was obtained. 94

95

## 96 Variables

97 Clinical data pertaining to the following variables were obtained for all patients: gender, age, BMI, 98 type of disease, transplantation stem cell source, degree of HLA incompatibility, disease status 99 before transplantation, conditioning regimen, total dose of corticosteroid, total protein, 100 total cholesterol, and rate of rehabilitation implementation. Data were obtained from the electronic 101 medical record system.

102

## 103 **Evaluation of physical functions**

An evaluation of physical function was conducted based on the knee extensor strength and 104six-minute walk distance (6MWD) test. Knee extensor strength was measured using the IsoForce 105GT-330 (OG Giken Co., Ltd., Okayama, Japan) during isometric contraction for 3 seconds. With 106 the patient in a sitting position with the hip and knee at an angle of 90°, the force sensor was placed 1071085 cm above the lateral malleolus. The better of two trials was used as the score. Torque was calculated by multiplying strength by the lever arm and was expressed as a percentage of body 109 weight (Nm/kg) [11]. The 6MWD test was conducted according to the protocol recommended by 110the American Thoracic Society [12]. The course set a straight course of 30 m in the corridor and 111 1126MWD was measured under maximum effort.

113

## 114 **Time of Evaluation**

Evaluation of each physical function was carried out before transplantation (i.e. before conditioning), after transplantation (i.e. after engraftment of transplanted stem cells), and at discharge (i.e. final intervention day of rehabilitation). As a criterion for the engraftment, the number of neutrophils exceeding  $0.5 \times 10^{10} / \mu$ L for three consecutive days was confirmed, and the chimerism analysis in bone marrow examination was performed.

## 121 Statistical analysis

122 SPSS software ver18.0 was used for statistical analysis. We considered two-sided p-values <0.05 as 123 statistically significant. Statistical analysis used iterative measurement variance analysis to compare 124 each item, and one-way ANOVA for comparison between groups at one time, and was corrected by 125 Bonferroni method. The relevance between each physical function, rate of rehabilitation, and total 126 corticosteroid dose was examined using Pearson's moment correlation analysis.

127

## 128 Exercise therapy program for allo-HSCT patients at Kyoto university hospital (Figure II)

The subjects of this study were undergoing rehabilitation interventions prior to transplantation. The 129contents of exercise therapy are carried out five times a week with 20 to 40 minutes of stretching, 130strength training, walking, and using bicycle ergometer. Exercise intensity is set to be "somewhat 131strong" in the Borg scale [13]. The bicycle ergometer calculates the target heart rate using the 132Karvonen Formula and sets it to 40% of the maximum intensity [14]. The clean room is a single 133room (ISO standard: class 5-6) with a toilet and a shower installed. In addition, hospital has clean 134management (ISO standard: class 8) for the entire ward and it is possible to exercise inside the ward 135at times outside of visiting hours. Exercise therapy during the aseptic management period is carried 136 out during the hours when patients can exercise inside the ward. 137

138

## 139 Diagnosis of acute GVHD

151	Patient background and treatment characteristics
150	Results
149	
148	course.
147	taxonomy. The final determination of severity was taken as the highest severity during the clinical
146	skin, liver, upper GI tract, and gut involvement according to the classification by Glucksberg's
145	Acute GVHD is clinically graded and staged in severity (grades I to IV) depending on the extent of
144	considered and excluded.
143	performed for proper diagnosis, when competing causes for isolated abnormalities had to be
142	diagnosis was frequently not straightforward. Skin, gastrointestinal tract, and liver biopsies were
141	diarrhea, and elevation of bilirubin within the first several weeks of transplantation. However, the
140	The diagnosis of acute GVHD can be made on clinical grounds in patients presenting with a rash,

Among the patients, 54% developed acute GVHD. The mean age of the patients without acute 152GVHD was 45.5(21-66) years, and that of patients with acute GVHD was 45.5(19-66) years. 153Among patients who did not develop acute GVHD, 23 were in complete remission, while 12 were 154in non-remission at transplantation. Among patients who developed acute GVHD, 24 were in 155complete remission, while 17 were in non-remission at transplantation. Characteristics of the 156157patients and treatment contents according to the severity of acute GVHD are shown in Table 1. Among patients with acute GVHD, 32% had grade I, 54% had grade II, and 15% had grade III-IV 158159disease. There was no significant difference in the patient background characteristics and treatment 160 contents at transplantation. There was no significant difference in number of engraftment days 161 between the groups. However, length of hospital days after transplantation was significantly longer 162 in Grade II and Grade III-IV groups than that in the non-GVHD group (Grade II, p<0.01; Grade 163 III-IV, p<0.01) (Figure III). Total protein did not show any significant change in any of the groups 164 (Figure IV).

165

## 166 Changes in physical function and rehabilitation implementation rate

In the non-GVHD and Grade I groups, the 6MWD significantly decreased from before 167transplantation to after transplantation (non-GVHD, p < 0.01; Grade I, p < 0.01), and it recovered 168 169 significantly at the time of discharge (non-GVHD, p<0.01; Grade I, p<0.01). In the Grade II group, the knee extensor strength and 6MWD significantly decreased from before transplantation to after 170transplantation (p < 0.01), and it recovered significantly at the time of discharge (p < 0.01) (Figure IV). 171In the Grade III-IV groups, the knee extensor strength significantly decreased from before 172transplantation to after transplantation (p < 0.01), and it did not recover significantly at the time of 173discharge. On the other hand, 6MWD significantly decreased from before transplantation to after 174transplantation, and it recovered significantly at the time of discharge. The decrease in 6MWD at 175the time of discharge remained significant compared to that at admission (p < 0.01). 176

In the Grade III-IV groups, the rehabilitation implementation rate significantly decreased from pre-HSCT period to post-HSCT discharge (p<0.01). In the Grade III-IV groups, the rehabilitation implementation rate during post-HSCT discharge significantly decreased compared to the 180non-GVHD groups, Grade I and II groups (non-GVHD, p < 0.01; Grade I, p < 0.01; Grade II, p < 0.01).181Additionally, total rehabilitation implementation rate also significantly decreased in Grade III-IV182group compared to the non-GVHD and Grade II groups (non-GVHD, p < 0.01; Grade II, p < 0.01)183(Figure V).

There was no significant correlation between knee extensor strength and the rehabilitation implementation rate (r=0.28, p<0.08). However, 6MWD showed a significant correlation with the rehabilitation implementation rate (r=0.40, p<0.01). There was a negative correlation between rate of change of knee extensor strength and total corticosteroid dose (r=-0.37, p<0.03). On the other hand, there was no correlation between the rate of change of 6MWD and total corticosteroid dose (r=-0.25, p<0.17) (Figure V).

190

#### 191 Discussion

Acute GVHD after allogeneic HSCT has been reported to suppress physical function after 192transplantation [2,15,16]. However, there is no report that examines the influence of differences in 193the severity of acute GVHD on the clinical courses and physical function after transplantation in 194detail. In this study, 54% of patients developed acute GVHD with 32% Grade I, 54% Grade II, and 19515% Grade III-IV based on severity. Grucksberg's classification focuses mainly on the symptoms of 196 197skin, liver, and intestinal tract, and its grade increases as the symptoms become severe. In this study, there was no significant difference in the number of engraftment days between groups regardless of 198199 the degree of severity of acute GVHD. However, the number of hospital days prolonged with the

200increase in acute GVHD grade level, requiring hospitalization for about 80 days in Grade III-IV group. When acute GVHD develops, the treatment method changes depending on THE severity. In 201case of mild acute GVHD, concentration of cyclosporine or tacrolimus in the blood is measured and 202 adjusted to an appropriate concentration [17]. On the other hand, in case of moderate or more acute 203GVHD, corticosteroid therapy is usually selected as the initial treatment. If it becomes severe, 204corticosteroid treatment may be insufficient and secondary therapies (anti-thymocyte globulin, 205mesenchymal stem cell, etc.) are required [18-21]. Therefore, in the Grade III-IV group, the number 206207of hospital days increases due to prolonged therapeutic intervention for acute GVHD after 208 transplantation.

Studies focusing on changes in physical functions after allo-HSCT have shown that exercise 209 tolerance and lower limb muscle strength decrease in the early stage of transplantation [22-26]. In 210211the early stages after transplantation, the amount of physical activity decreases due to environmental 212restrictions specific to transplantation, such as clean room management besides transplant-related complications. On the other hand, it has been reported that the amount of physical activity increases 213and physical function improves when the transplanted donor stem cells engraft and the clean room 214management ends [27]. In the non-GVHD and the grade I-II groups, the rehabilitation 215implementation rate was maintained at a high level throughout the transplantation treatment process. 216Furthermore, since there was little therapeutic intervention for acute GVHD at the early stage of 217transplantation, it was considered that physical function was suppressed due to the decrease in the 218219amount of physical activity associated with clean room management at the early stage of

transplantation. We predicted that the physical function after engraftment improved by 220221rehabilitation intervention. On the other hand, in Grade III-IV group, physical function decreased significantly after transplantation similar to grade I-II group. Additionally, at the time of discharge, 222the patients did not show sufficient recovery of physical function compared to before 223transplantation. In other words, even if the hospitalization period is extended, it is difficult to restore 224physical function in Grade III-IV group. Grade III-IV group showed significantly lower values of 225rehabilitation implementation rate compared to the other groups, which inhibited the recovery of 226227physical function. As acute GVHD becomes severe, gastrointestinal symptoms appear in addition to skin symptoms. From a nutritional point of view, when acute GVHD becomes severe, oral nutrition 228intake decreases and central venous nutrition is forced to prevent weight loss [28]. Especially when 229the intestinal tract GVHD becomes severe, nutrient absorption from the intestinal tract is inhibited. 230Hence, the lower nutritional intake accompanying severe acute GVHD may have influenced the 231recovery of the physical function. 232

Regarding the change in each physical function depending on the severity of acute GVHD, knee extensor strength of Grade II and III-IV groups decreased significantly after transplantation. One of the factors that reduced knee extensor strength is disuse muscle atrophy associated with an increase in bed rest. It has been reported that the muscular strength and cross-sectional area of the quadriceps muscle decreases as bed rest increases [29]. Hence, an increase in bedtime due to severe acute GVHD was considered as one of the factors that affected knee extensor strength weakness. In addition, corticosteroid administration is also conceivable as a factor that reduces knee extensor

strength. High dose corticosteroid therapy is selected as a treatment option when acute GVHD 240becomes severe [18-21]. Corticosteroid-induced muscle atrophy, which affects Type II fiber 241(fast-twitch muscle fiber), is a complication of corticosteroid administration [30-31]. Knee extensor 242strength is a method of evaluating muscular strength which occupies a large amount of Type II fiber 243[32]. Therefore, it was considered that the knee extensor strength significantly decreases due to the 244influence of high dose corticosteroid administration. In addition, it is suggested that in the group 245requiring a high dose of corticosteroid, the lower limb muscular strength may not sufficiently 246recover even at discharge. Our results showed significantly reduced 6MWD after transplantation 247regardless of the severity of acute GVHD, supporting the results from previous reports [33-34]. 248However, the knee extensor strength and the 6MWD did not show the same change in each group. 249The 6MWD is a method of evaluating the entire endurance performance, which includes various 250251other factors apart from the lower limb muscular strength. In this study, the rehabilitation implementation rate and the rate of change of the 6MWD were found to have a significant 252correlation. The 6MWD recovered significantly due to successful implementation of rehabilitation 253in patients with mild acute GVHD and those who did not develop acute GVHD. In the Grade III-IV 254group, reduction of lower limb muscle strength due to corticosteroid administration was also 255considered as a factor to inhibit recovery of 6MWD, in addition to factors such as difficulty in 256rehabilitation accompanied by severe GVHD. As a result, we concluded that continued 257258rehabilitation is necessary to restore endurance performance. The limitation of this study is that we were unable to examine physical activity after transplantation in further detail. Furthermore, there is 259

a possibility of selection bias since 55 patients were not evaluated for physical function.

261

## 262 Conclusion

We retrospectively investigated the effect of the severity of acute GVHD on physical function after 263allo-HSCT in detail for the first time. The results indicate that if the severity is mild even after 264developing an acute GVHD following allo-HSCT, there is a gradual decline in physical function, 265which improves at discharge. However, if it becomes severe, it is difficult to implement 266rehabilitation and the deterioration of physical function becomes prominent. Therefore, physical 267function declines even at discharge. If acute GVHD becomes severe, physical function may further 268deteriorate, hence, it is imperative to rethink the rehabilitation approach for patients with severe 269GVHD. 270

271

## 272 Acknowledgements

We are grateful to the medical, nursing, and laboratory staff of the participating departments for their contributions to this study.

**Funding information** 

none 276 none

- 278 **Compliance with ethical standards**
- 279 Conflict of interest

280 The authors declare that they have no conflict of interest.

### 281 Ethical approval

This study was approved by the Institutional Review Board of Kyoto University Hospital conducted in accordance with the international ethical recommendations stated in the Japanese Good Clinical Practice Guidelines.

## 285 **References**

- 286 1. The Japanese Data Center for Hematopoietic Cell Transplantation, The Japan Society for
- 287 Hematopoietic Cell Transplantation (2016) Hematopoietic Cell Transplantation in Japan Annual

288 Report of Nationwide Survey. https://doi.org/10.11386/jst.52.2-3\_184

- 289 2. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin
- 290 R, Giralt S (2006) Steroid myopathy in patients with acute graft-versus-host disease treated with
- high dose steroid therapy. Bone Marrow Transplant 38(4):299-303. 10.1038/sj.bmt.1705435
- 292 3. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin
- 293 RS, O'Donnell MR, Parker PM et al (1993) Cyclosporine, methotrexate, and prednisone Compared
- with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med
- 295 329(17):1225-30. 10.1056/NEJM199310213291703
- 296 4. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney
- 297 K, McDonald GB, Sanders JE et al (1990) Appelbaum FR et al. A retrospective analysis of therapy
- for acute graft versus-host disease initial treatment. Blood 76(8):1464-72.
- 299 5. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani

300	S, Takehana K, Sano M, Fukuda K, Suematsu M, Morimoto C, Tanaka H (2011) Crosstalk between
301	glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 13(2):170-82.
302	10.1016/j.cmet.2011.01.001

- 303 6. Minetto MA, Lanfranco F, Motta G, Allasia S, Arvat E, Antona GD (2011) Steroid myopathy:
  304 some unresolved issues. J. Endocrinol. Invest. 34, 370–375.
- 305 7. Schäcke H, Döcke WD, Asadullah K (2002) Asadullah K. Mechanisms involved in the side
  306 effects of glucocorticoids. Pharmacol Ther 96(1):23-43.
  307 https://doi.org/10.1016/S0163-7258(02)00297-8
- 8. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in
   cancer patients. Neurology 48(5) 1234–1238. https://doi.org/10.1212/WNL.48.5.1234
- 310 9. Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP (2013) Glucocorticoid-induced skeletal
- 311 muscle atrophy. Int J Biochem Cell Biol 45(10):2163-72. 10.1016/j.biocel.2013.05.036
- 312 10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED
- 313 (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from
- HL-A-matched sibling donors. Transplantation 18(4):295-304.
- 11. Nankaku M, Tsuboyama T, Kakinoki R, Akiyama H, Nakamura T (2011) Prediction of
  ambulation ability following total hip arthroplasty. J Orthop Sci 16(4):359-63.
  10.1007/s00776-011-0067-x
- 12. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002)
- ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111-7.

- 321 13. Borg GA (1982) Psychophysical bases of perceived exertion. Medicine and Science in Sports
  322 and Exercise 14(5):377-81.
- 14. Robert A, Roberto (2002) The surprising history of "HRmax=220-age" equation. J Exercise
  Physiologists 5(2):1-10.
- 15. Kovalszki A, Schumaker GL, Klein A, Terrin N, White AC (2008) Reduced respiratory and
  skeletal muscle strength in survivors of sibling or unrelated donor hematopoietic stem cell
  transplantation. Bone Marrow Transplant 41(11):965-9. 10.1038/bmt.2008.15
- 328 16. Ishikawa A, Okata Y, Kamisako M, Suzuki T, Miyata C, Tsuji T, Matsumoto H, Kato J, Mori T,
- 329 Okamoto S, Liu M (2019) Factors affecting lower limb muscle strength and cardiopulmonary
- 330 fitness after allogeneic hematopoietic stem cell transplantation. Support Care Cancer
  331 27(5):1793-1800. 10.1007/s00520-018-4433-5.
- 332 17. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, Scarisbrick JJ, Taylor
- 333 PC, Hadzic N, Shaw BE, Potter MN et al (2012) Diagnosis and management of acute
- 334 graft-versus-host disease. Br J Haematol 158(1):30-45. 10.1111/j.1365-2141.2012.09129.x
- 18. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A (1990)
- 336 Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow
- transplantation : an analysis of clinical risk features and outcome. Blood 75(4):1024-30.
- 19. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF (1997) A Survey of the Prophylaxis and
- 339 Treatment of Acute GVHD in Europe : a report of the European Group for Blood and Marrow

- 340 Transplantation(EBMT). Bone Marrow Transplant 19(8):759-64. 10.1038/sj.bmt.1700745
- 341 20. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Beatty PG, Doney
- K, McDonald GB, Sanders JE (1990) A retrospective analysis of therapy for acute graft-versushost
  disease : initial treatment. Blood 76(8):1464-72.
- 21. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani
- BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA (2012) First- and second-line systemic
- 346 treatment of acute graft-versus-host disease : recommendations of the American Society of Blood
- and Marrow Transplantation. Biology of blood and marrow transplantation. Biol Blood Marrow
- 348 Transplant 18(8):1150-63. 10.1016/j.bbmt.2012.04.005
- 349 22. Mello M, Tanaka C, Dulley FL (2003) Effects of an exercise program on muscle performance in
- patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 32(7):723-8.
- 351 10.1038/sj.bmt.1704227
- Baumann FT, Kraut L, Schüle K, Bloch W, Fauser AA (2009) A controlled randomized study
   examining the effects of exercise therapy on patients undergoing haematopoietic stem cell
- transplantation. Bone Marrow Transplant 45(2):355-62. 10.1038/bmt.2009.163
- 24. Rovelli A, Pezzini C, Silvestri D, Tana F, Galli MA, Uderzo C (1995) Cardiac and
  respiratory function after bone marrow transplantation in children with leukaemia. Bone Marrow
  Transplant 16(4) 571-76.
- 25. Baumann FT, Zopf EM, Nykamp E, Kraut L, Schüle K, Elter T, Fauser AA, Bloch W (2011)
- 359 Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation:

360 benefits of a moderate exercise intervention. Eur J Haematol 87(2):148-56.
361 10.1111/j.1600-0609.2011.01640.x

362 26. Morishita S, Kaida K, Yamauchi S, Wakasugi T, Yoshihara S, Taniguchi K, Ishii S, Ikegame

- 363 K, Kodama N, Ogawa H, Domen K (2012) Gender differences in health-related quality of life,
- 364 physical function and psychological status among patients in the early phase following allogeneic
- haematopoietic stem cell transplantation. Psychooncology 22(5):1159-66. 10.1002/pon.3128
- 366 27. Jarden M, Baadsgaard M, Hovgaard D, Boesen E, Adamsen L (2009) A randomized trial on the
- 367 effect of a multimodal intervention on physical capacity, functional performance and quality of life
- in adult patients undergoing allogeneic SCT. Bone Marrow Transplant 43(9):725-37.
  10.1038/bmt.2009.27
- 28. Weisdorf SA, Lysne J, Wind D, Haake RJ, Sharp HL, Goldman A, Schissel K, McGlave
- 371 PB, Ramsay NK, Kersey JH (1987) Positive effect of prophylactic total parenteral nutrition on
- 372 long-term outcome of bone marrow transplantation. Transplantation 43(6):833-8.
- 29. Berg HE, Larsson L, Tesch PA (1997) Lower limb skeletal muscle function after 6wk of bed rest.
- 374 J Appl Physiol 82(1):182-8. 10.1152/jappl.1997.82.1.182
- 375 30. Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, Ross EJ (1983)
- 376 Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol (Oxf) 18(2):155-66.
- 377 31. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in
- 378 cancer patients. Neurology 48:1234-38. https://doi.org/10.1212/WNL.48.5.1234
- 379 32. Johnson MA, Polgar J, Weightman D, Appleton D (1973) Data on the distribution of fiber types

380	in	thirty-six	human	muscles.	J	Neurol	Sci	18(1):111-29.
381	https:	//doi.org/10.101	6/0022-510X	(73)90023-3				

382 33. Morishita S, Kaida K, Yamauchi S, Wakasugi T, Ikegame K, Ogawa H, Domen K (2017)

- 383 Relationship of physical activity with physical function and health-related quality of life in patients
- having undergone allogeneic haematopoietic stem-cell transplantation. Eur J Cancer Care(Engl)

385 26(4). 10.1111/ecc.12669

386 34. Takekiyo T, Dozono K, Nara S, Murayama Y, Minamihama N, Nakano N, Kubota A, Tokunaga


- M, Miyazono T, Takeuchi S, Takatsuka Y, Utsunomiya A (2017) Gender differences in physical
   function and muscle mass change in patients undergoing allogeneic hematopoietic stem cell
- 389 transplantation. Bone Marrow Transplant 52(10):1460-1462. 10.1038/bmt.2017.156
- 390

#### **Table I.** Patient background by severity of acute graft versus host disease.

	non-GVHD	Grade I	Grade II	Grade III-IV
	(n=35)	(n=13)	(n=22)	(n=6)
Gender (Men/Female) <sup>a</sup>	25/10	10/3	13/9	3/3
Age <sup>b</sup>	45.5±14.1	44.8±12.4	45.8±15.2	46.3±14.2
Body mass index, <i>kg/m<sup>2 b</sup></i>	21.7±3.7	21.8±3.6	21.3±3.9	22.3±2.5
Diagnosis (Leukemia/MDS/Lymphoma) <sup>a</sup>	24/6/5	8/2/3	12/6/4	4/1/1
Transplantation type	10/11/5	0/0/2	10/11/1	2/1/2
(Bone marrow/Cord blood/Peripheral blood) <sup>a</sup>	19/11/5	8/2/3	10/11/1	3/1/2
HLA (Matched relative/Matched unrelative) <sup>a</sup>	22/13	6/7	9/13	4/2
Complete remission (CR/non-CR) <sup>a</sup>	23/12	10/3	10/12	4/2
Conditioning (Myeloablative/Reduced intensity) <sup>a</sup>	20/15	9/4	18/4	4/2

- 392 MDS : myelodysplastic syndrome
- 393 HLA : Human Leukocyte Antigen
- <sup>a</sup> Values represents the number of patients in each category
- 395 <sup>b</sup> Values represents the mean  $\pm$  SD
- 396


#### Figure I. Study flow chart




#### Figure II. Physical therapy program before and after hematopoietic stem cell transplantation.


	Before transplantatio	'n				
Protocol	Two weeks before transplantation	Previous treatment	Transplantation	Engraftment	Engraftment-Discharge	
Intervention place	Rehabilitation room		Clean floor		Rehabilitation room	
	Physical function tests (pre)				Physical function tests (post/discharge)	
Program	•Stretching •Muscle strength exercise •Endurance training	•Stretching •Muscle strength e •Endurance trainir •Walking training	ıg		•Stretching •Muscle strength exercise •Endurance training	
	Hospital		Hospital ward		Hospital	

Figure III. Days of engraftment day and length of hospital days of the non-GVHD and acute GVHD groups. 



# **Figure IV**. Physical function evaluation for the non-GVHD and acute GVHD groups.






- 429 (a) Knee extensor strength of non-GVHD group and acute GVHD group.
- 430 (b) Six-minute walk distance of non-GVHD group and acute GVHD group.
- 431 (c) Total protein of non-GVHD group and acute GVHD group.
- 432 (d) Rate of rehabilitation of non-GVHD group and acute GVHD group.
- 433 \* : Significant difference between groups(*p*<0.01)
- 434 <sup>†</sup> : Significant difference at each time(p < 0.01)
- 435

428

Figure V. Relationship between each physical function and total corticosteroid administration,
 executing rate of rehabilitation.



## 438

439 (a)(b): Scatterplots illustrating the relationship between total corticosteroid dose and physical function change.

440 (c)(d): Scatterplots illustrating the relationship between executing rate of rehabilitation and physical function441 change.